CLChi Fung Lee

Chi Fung Lee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chi Fung Lee has a total of 98 co-authors. Here are the top co-authors by number of shared publications:

  • Rong Tian

    Mitochondria and Metabolism Center, Department of Anesthesiology & Pain Medicine, University of Washington, Seattle, WA

    13 shared publications
  • Reto Asmis

    Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC

    5 shared publications
  • Ying Ann Chiao

    Oklahoma Medical Research Foundation

    5 shared publications
  • Georgios Karamanlidis

    Department of Anesthesiology and Pain Medicine, Mitochondria and Metabolism Center, University of Washington School of Medicine, Seattle, Washington, United States of America

    4 shared publications
  • Hong Seok Kim

    The University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229. USA

    4 shared publications
  • Lorena Garcia-Menendez

    From Mitochondria and Metabolism Center (C.F.L., L.G.-M., Y.C., N.D.R., R.T.), Department of Anesthesiology and Pain Medicine (C.F.L., L.G.-M, Y.C., N.D.R., R.T.), Department of Genome Sciences (J.D.C., J.E.B.), Department of Pathology (Y.A.C.), and Department of Medicinal Chemistry (J.S.E., Y.A.G., D.R.G.), University of Washington, Seattle, WA

    4 shared publications

Latest Publications

  • Open Access

    PFKFB2 Gates a Relationship Between Cardiac Glycolytic Regulation and Electrophysiological Function

    by Kylene M. Harold, Harris E. Blankenship, Keaton E. Minor, Abigail S. Mulligan, Brooke L. Loveland, Chi Fung Lee, Michael Kinter, David A. Kass, Stavros Stavrakis, Michael J. Beckstead, et al.

    BACKGROUND: The cardiac isoform of phosphofructokinase-2/fructose 2,6-biphosphatase (PFKFB2) is the heart’s strongest glycolytic regulator but is degraded in the absence of insulin signaling. This makes PFKFB2 loss critical to understand in metabolic heart disease, of which impaired insulin signaling is a hallmark. Prolongation of the QT interval, risk of arrhythmia, and sudden cardiac death are also augmented in metabolic heart disease, raising a question as to whether crosstalk between glycolytic dysregulation and electrophysiological dysfunction exists. METHODS: We therefore assessed the impact of PFKFB2 loss on cardiac electrophysiology using a cardiomyocyte-specific PFKFB2 knockout mouse model (cKO) and litter-matched controls. To do so, we employed electrocardiography in the fed state and following 12 hours of fasting, examining physiology both at baseline and in the presence of an acute stimulant stress. To further investigate the arrhythmia mechanism, we used patch-clamp electrophysiology and IonOptix Ca 2+ transient measurements in ventricular cardiomyocytes isolated from control and cKO hearts. RESULTS: The hearts of cKO mice exhibited prolonged repolarization, marked by QT and action potential duration prolongations. This occurred with impaired Ca 2+ reuptake and increased spontaneous Ca 2+ release events in ventricular cardiomyocytes. The latter were upregulated via O-GlcNAcylation, a post-translational modification enhanced in the fed state in cKO hearts. Ultimately, these changes culminated in ventricular tachyarrhythmia in cKO mice, which was enhanced in the fed relative to the fasted state. CONCLUSIONS: These data suggest that in the presence of sufficient glucose availability, cardiac glycolytic dysregulation at the phosphofructokinase nexus is sufficient to promote cardiac electrophysiological instability.

  • SARM1 Regulates BNIP3-Mediated Mitochondrial Quality Control in Diabetic Hearts

    by Hina Lateef Nizami, Keaton E. Minor, Patrycja E. Szybowska, Ignacy Gorecki, Lindsay Best, Christine M. Light, Pratyaksh Singhal, Xiaolu A. Cambronne, Ying Ann Chiao, Chi Fung Lee


  • Open Access

    PFKFB2 Gates a Relationship Between Cardiac Glycolytic Regulation and Electrophysiological Function

    by Kylene M. Harold, Harris E. Blankenship, Keaton Minor, Abigail Mulligan, Brooke Loveland, Chi Fung Lee, Michael Kinter, David Kass, Stavros Stavrakis, Michael J. Beckstead, et al.

    Background: The cardiac isoform of phosphofructokinase-2/fructose 2,6-bisphosphatase (PFKFB2) is the heart’s strongest glycolytic regulator but is degraded in the absence of insulin signaling. This makes PFKFB2 loss critical to understand in metabolic heart disease, of which impaired insulin signaling is a hallmark. Prolongation of the QT interval, risk of arrhythmia, and sudden cardiac death are also augmented in metabolic heart disease, raising a question as to whether potential crosstalk between glycolytic dysregulation and electrophysiological dysfunction exists. Methods: We therefore assessed the impact of PFKFB2 loss on cardiac electrophysiology using a cardiomyocyte-specific PFKFB2 knockout mouse model (cKO) and litter-matched controls (CON). To do so, we employed electrocardiography in the fed state and following 12 hours of fasting, examining physiology both at baseline and in the presence of an acute stimulant stress. To further investigate the arrhythmia mechanism, we used patch-clamp electrophysiology and IonOptix Ca 2+ transient measurements in ventricular cardiomyocytes isolated from CON and cKO hearts. Results: The hearts of cKO mice exhibited prolonged repolarization, marked by QT and action potential duration prolongations. This occurred with impaired Ca 2+ reuptake and increased spontaneous Ca 2+ release events in ventricular cardiomyocytes. Ultimately, these changes culminated in ventricular tachyarrhythmia in cKO mice, which was enhanced in the fed relative to the fasted state. Conclusion: These data suggest that in the presence of sufficient glucose availability, cardiac glycolytic dysregulation at the phosphofructokinase nexus is sufficient to promote cardiac electrophysiological instability. Clinical Perspective: What is Known: Metabolic heart diseases, such as heart failure with preserved ejection fraction and diabetic cardiomyopathy, are associated with heightened risks of arrhythmogenesis and sudden cardiac death. What the Study Adds: Here, we show for the first time that PFKFB2 is decreased in human hearts with heart failure with preserved ejection fraction. Furthermore, we show that loss of cardiac PFKFB2 is sufficient to promote impaired ventricular repolarization at baseline and ventricular tachyarrhythmia upon stress test. This identifies PFKFB2 stabilization and activation as key potential targets in conferring electrophysiological stability in metabolic heart disease.


  • Emerging interactions between mitochondria and NAD+ metabolism in cardiometabolic diseases

    by Azadeh Nasuhidehnavi, Weronika Zarzycka, Ignacy Górecki, Ying Ann Chiao, Chi Fung Lee


  • Sexually dimorphic effects of SARM1 deletion on cardiac NAD+ metabolism and function

    by Hina Lateef Nizami, Keaton E. Minor, Ying Ann Chiao, Christine M. Light, Chi Fung Lee

    We examined the effects of SARM1 deletion on NAD+ pool, transcripts of NAD+ metabolism, and fibrotic pathway for the first time in mouse hearts. We observed the sexually dimorphic effects of SARM1 deletion. How these sex-dependent effects influence the outcomes of SARM1 deficiency in male and female mice in responses to cardiac stresses warrant further investigation. The elevation of cardiac NAD+ pool by SARM1 deletion provides evidence that targeting SARM1 may reverse disease-related NAD+ decline.


  • Harnessing NAD+ Metabolism as Therapy for Cardiometabolic Diseases

    by Akash Chakraborty, Keaton E. Minor, Hina Lateef Nizami, Ying Ann Chiao, Chi Fung Lee

    Purpose of the Review This review summarizes current understanding on the roles of nicotinamide adenine dinucleotide (NAD+) metabolism in the pathogeneses and treatment development of metabolic and cardiac diseases. Recent Findings NAD+ was identified as a redox cofactor in metabolism and a co-substrate for a wide range of NAD+-dependent enzymes. NAD+ redox imbalance and depletion are associated with many pathologies where metabolism plays a key role, for example cardiometabolic diseases. This review is to delineate the current knowledge about harnessing NAD+ metabolism as potential therapy for cardiometabolic diseases. The review has summarized how NAD+ redox imbalance and depletion contribute to the pathogeneses of cardiometabolic diseases. Therapeutic evidence involving activation of NAD+ synthesis in pre-clinical and clinical studies was discussed. Summary While activation of NAD+ synthesis shows great promise for therapy, the field of NAD+ metabolism is rapidly evolving. Therefore, it is expected that new mechanisms will be discovered as therapeutic targets for cardiometabolic diseases.


  • NAD + Redox Imbalance in the Heart Exacerbates Diabetic Cardiomyopathy

    by Ying Ann Chiao, Akash Deep Chakraborty, Christine M. Light, Rong Tian, Junichi Sadoshima, Xiaojian Shi, Haiwei Gu, Chi Fung Lee

    Background: Diabetes is a risk factor for heart failure and promotes cardiac dysfunction. Diabetic tissues are associated with nicotinamide adenine dinucleotide (NAD + ) redox imbalance; however, the hypothesis that NAD + redox imbalance causes diabetic cardiomyopathy has not been tested. This investigation used mouse models with altered NAD + redox balance to test this hypothesis. Methods: Diabetic stress was induced in mice by streptozotocin. Cardiac function was measured by echocardiography. Heart and plasma samples were collected for biochemical, histological, and molecular analyses. Two mouse models with altered NAD + redox states (1, Ndufs4 [NADH:ubiquinone oxidoreductase subunit S4] knockout, cKO, and 2, NAMPT [nicotinamide phosphoribosyltranferase] transgenic mice, NMAPT) were used. Results: Diabetic stress caused cardiac dysfunction and lowered NAD + /NADH ratio (oxidized/reduced ratio of nicotinamide adenine dinucleotide) in wild-type mice. Mice with lowered cardiac NAD + /NADH ratio without baseline dysfunction, cKO mice, were challenged with chronic diabetic stress. NAD + redox imbalance in cKO hearts exacerbated systolic (fractional shortening: 27.6% versus 36.9% at 4 weeks, male cohort P P + redox imbalance promoted superoxide dismutase 2 acetylation, protein oxidation, troponin I S150 phosphorylation, and impaired energetics in diabetic cKO hearts. Importantly, elevation of cardiac NAD + levels by NAMPT normalized NAD + redox balance, alleviated cardiac dysfunction (fractional shortening: 40.2% versus 24.8% in cKO:NAMPT versus cKO, P P + redox imbalance to regulate acetylation and phosphorylation is a critical mediator of the progression of diabetic cardiomyopathy and suggest the therapeutic potential for diabetic cardiomyopathy by harnessing NAD + metabolism.